Literature DB >> 19898867

Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma.

Xingjun Yao1, Gang Zhao, Hongfa Yang, Xinyu Hong, Li Bie, Guojin Liu.   

Abstract

PURPOSE: High-mobility group box 1 (HMGB1) has been implicated in a variety of biologically important processes, including transcription, DNA repair, V(D)J recombination, differentiation, development, and extracellular signaling. The increased expression of HMGB1 has been described in colorectal cancer (CRC). However, there is no report about the correlation of HMGB1 with clinicopathologic features, including the survival of patients with CRC.
METHODS: In present study, we investigated HMGB1 expression and its prognostic significance in CRC by performing immunohistochemical analysis, using a total of 192 paraffin-embedded archival CRC samples. Moreover, disruption of endogenous HMGB1 protein through a siRNA knockdown technique was performed to investigate the possible role of HMGB1 in the process of tumor invasion and metastasis.
RESULTS: Overexpression of HMGB1 was shown in 55.7% cases. Statistical analysis showed that HMGB1 expression was positively correlated with tumor invasion (P = 0.048), lymph node metastasis (P = 0.011), distant metastasis (P = 0.031), and Duke's stage (P = 0.029) of CRC patients. Patients with higher HMGB1 expression had shorter overall survival time, whereas patients with lower level of HMGB1 had better survival. Multivariate analysis suggested that HMGB1 expression might be an independent prognostic indicator for the survival of patients with CRC. Disruption of endogenous HMGB1 protein through a siRNA knockdown technique was shown to suppress substantially the invasion ability of SW620 cells.
CONCLUSIONS: Our results suggest that HMGB1 protein is a valuable marker for progression of CRC patients. High HMGB1 expression is associated with poor overall survival in patients with CRC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19898867     DOI: 10.1007/s00432-009-0706-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  22 in total

1.  Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients.

Authors:  R Masunaga; H Kohno; D K Dhar; S Ohno; M Shibakita; S Kinugasa; H Yoshimura; M Tachibana; H Kubota; N Nagasue
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

Review 2.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.

Authors:  Michael T Lotze; Kevin J Tracey
Journal:  Nat Rev Immunol       Date:  2005-04       Impact factor: 53.106

3.  Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1.

Authors:  Anke Meyer; Andrea Staratschek-Jox; Anette Springwald; Heiner Wenk; Jurgen Wolf; Claudia Wickenhauser; Jörn Bullerdiek
Journal:  Leuk Lymphoma       Date:  2008-06

4.  Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation.

Authors:  Yon Rak Choi; Hyunki Kim; Hyun Ju Kang; Nam-Gyun Kim; Jung Jin Kim; Kang-Sik Park; Young-Ki Paik; Hyun Ok Kim; Hoguen Kim
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

5.  Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma.

Authors:  D Wu; Y Ding; S Wang; Q Zhang; L Liu
Journal:  J Pathol       Date:  2008-10       Impact factor: 7.996

6.  Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin.

Authors:  Ashok Sharma; Ruma Ray; Moganty R Rajeswari
Journal:  Cancer Invest       Date:  2008-10       Impact factor: 2.176

7.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

8.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.

Authors:  Paola Scaffidi; Tom Misteli; Marco E Bianchi
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

9.  Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer.

Authors:  Hye Won Chung; Sang-Guk Lee; Heejung Kim; Duck Jin Hong; Jae Bock Chung; David Stroncek; Jong-Baeck Lim
Journal:  J Transl Med       Date:  2009-05-28       Impact factor: 5.531

10.  Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation.

Authors:  Roberta Palumbo; Maurilio Sampaolesi; Francesco De Marchis; Rossana Tonlorenzi; Sara Colombetti; Anna Mondino; Giulio Cossu; Marco E Bianchi
Journal:  J Cell Biol       Date:  2004-01-26       Impact factor: 10.539

View more
  40 in total

1.  p53/HMGB1 complexes regulate autophagy and apoptosis.

Authors:  Kristen M Livesey; Rui Kang; Philip Vernon; William Buchser; Patricia Loughran; Simon C Watkins; Lin Zhang; James J Manfredi; Herbert J Zeh; Luyuan Li; Michael T Lotze; Daolin Tang
Journal:  Cancer Res       Date:  2012-02-16       Impact factor: 12.701

2.  The combination of a nuclear HMGB1-positive and HMGB2-negative expression is potentially associated with a shortened survival in patients with pancreatic ductal adenocarcinoma.

Authors:  Toru Takeda; Hiroto Izumi; Shohei Kitada; Hidetaka Uramoto; Takashi Tasaki; Li Zhi; Xin Guo; Yuichiro Kawatsu; Tomoko Kimura; Seichi Horie; Atsunori Nabeshima; Hirotsugu Noguchi; Ke-Yong Wang; Yasuyuki Sasaguri; Kimitoshi Kohno; Sohsuke Yamada
Journal:  Tumour Biol       Date:  2014-07-26

3.  Expression and clinical significance of Sirt1 in colorectal cancer.

Authors:  Deng-Feng Yu; Su-Juan Jiang; Zhi-Peng Pan; Wei-Dong Cheng; Wen-Jun Zhang; Xiao-Kun Yao; Yu-Cheng Li; Yong-Zhi Lun
Journal:  Oncol Lett       Date:  2015-12-01       Impact factor: 2.967

4.  High-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistance.

Authors:  Zhe Bao Wu; Lin Cai; Shao Jian Lin; Zhen Kun Xiong; Jiang Long Lu; Ying Mao; Yu Yao; Liang Fu Zhou
Journal:  Neuro Oncol       Date:  2013-07-04       Impact factor: 12.300

5.  Correlation of High Mobility Group Box-1 Protein (HMGB1) with Clinicopathological Parameters in Primary Retinoblastoma.

Authors:  Mithalesh Kumar Singh; Lata Singh; Neelam Pushker; Seema Sen; Anjana Sharma; Feeroj Ahamad Chauhan; Seema Kashyap
Journal:  Pathol Oncol Res       Date:  2015-06-30       Impact factor: 3.201

6.  The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.

Authors:  Chen Chuangui; Tang Peng; Yu Zhentao
Journal:  Pathol Oncol Res       Date:  2012-04-29       Impact factor: 3.201

7.  High-mobility group boxes mediate cell proliferation and radiosensitivity via retinoblastoma-interaction-dependent and -independent mechanisms.

Authors:  Li-Li Wang; Qing-Hui Meng; Yang Jiao; Jia-Ying Xu; Chun-Min Ge; Ju-Ying Zhou; Eliot M Rosen; Hai-Chao Wang; Sai-Jun Fan
Journal:  Cancer Biother Radiopharm       Date:  2012-06-01       Impact factor: 3.099

8.  MiR-216b functions as a tumor suppressor by targeting HMGB1-mediated JAK2/STAT3 signaling way in colorectal cancer.

Authors:  Xiaoxiang Chen; Xiangxiang Liu; Bangshun He; Yuqin Pan; Huiling Sun; Tao Xu; Xiuxiu Hu; Shukui Wang
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

9.  Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer.

Authors:  Chu-Biao Zhao; Ji-Ming Bao; Yong-Jie Lu; Tong Zhao; Xin-Hua Zhou; Da-Yong Zheng; Shan-Chao Zhao
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

Review 10.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.